Ovarian cancer often returns
A vaccine for ovarian cancer has produced "encouraging" results in preliminary trials, US scientists say.
The vaccine is designed to enhance the body's own immune response to the cancer, said the Roswell Park Cancer Institute, based in Buffalo, New York.
Most patients with advanced disease respond to chemotherapy, but more than 70% die from a recurrence of the cancer within five years of diagnosis.
Cancer Research UK welcomed the study but said further trials were needed.
Details of the study appear in Proceedings of the National Academy of Sciences.
No comments:
Post a Comment